Marshall Wace’s MoonLake Immunotherapeutics MLTX Stock Holding History

Marshall Wace’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.7M	Buy	550,351 +439,020	+394%	+$7.96M	0.01%	1010
2026 Q1	$2.08M	Buy	+111,331	New	+$1.84M	﹤0.01%	1763
2025 Q4	–	Sell	-321,109	Closed	-$2.3M	–	3268
2025 Q3	$2.3M	Sell	321,109 -208,102	-39%	-$10.8M	﹤0.01%	1547
2025 Q2	$25M	Sell	529,211 -111,706	-17%	-$4.55M	0.03%	505
2025 Q1	$25M	Sell	640,917 -604,382	-49%	-$26M	0.03%	458
2024 Q4	$67.4M	Buy	1,245,299 +90,914	+8%	+$4.64M	0.08%	222
2024 Q3	$58.2M	Buy	1,154,385 +55,755	+5%	+$2.61M	0.07%	241
2024 Q2	$48.3M	Buy	1,098,630 +587,684	+115%	+$24.9M	0.06%	272
2024 Q1	$25.7M	Buy	+510,946	New	+$27.7M	0.04%	430
2023 Q4	–	Sell	-30,451	Closed	-$1.74M	–	2449
2023 Q3	$1.74M	Sell	30,451 -27,932	-48%	-$1.54M	﹤0.01%	1288
2023 Q2	$2.98M	Buy	+58,383	New	+$1.57M	0.01%	1226
2022 Q2	–	Sell	-653,872	Closed	-$7.26M	–	3690
2022 Q1	$7.26M	Buy	653,872 +120,968	+23%	+$1.2M	0.01%	1105
2021 Q4	$5.27M	Buy	+532,904	New	+$5.3M	0.01%	1313

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace's MLTX Position: Q2 2026 in Review

Marshall Wace increased its MoonLake Immunotherapeutics (MLTX) stake by 394% in Q2 2026, buying an estimated $7.96M and bringing the position to 550,351 shares worth $10.7M. The position accounts for 0.01% of the portfolio, ranked #1010.

Marshall Wace first reported a position in MLTX in Q4 2021 and has held it in 13 quarters since. The position peaked at $67.4M in Q4 2024. 172 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Marshall Wace held 550,351 shares of MoonLake Immunotherapeutics worth $10.7M as of Q2 2026.
Marshall Wace bought 439,020 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $7.96M.
MoonLake Immunotherapeutics made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #1010 holding.
Marshall Wace first reported a position in MoonLake Immunotherapeutics in Q4 2021 and has held it in 13 quarters since.
Marshall Wace's MoonLake Immunotherapeutics position peaked at $67.4M in Q4 2024.
172 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.